What is DASS-167?

The DASS-167 was first introduced in 1995 by Ron Andsher, Peter Lovibond, and Sydney Lovibond, as an extension of the original DASS-21 scale. The developers aimed to create a more comprehensive assessment tool that could capture the complexities of mental health, beyond just depression and anxiety. The DASS-167 was designed to assess three distinct but interrelated constructs: depression, anxiety, and stress.

Advantages and Limitations

Advantages:

Interpretation and Cut-Off Scores

Future studies will focus on optimizing the pharmacokinetics and safety of DASS-167, as well as evaluating its efficacy in clinical trials. The development of DASS-167 as a therapeutic agent may provide a much-needed treatment option for patients with COVID-19, particularly those who are resistant or intolerant to existing therapies.

Dass-167 ~repack~ May 2026

What is DASS-167?

The DASS-167 was first introduced in 1995 by Ron Andsher, Peter Lovibond, and Sydney Lovibond, as an extension of the original DASS-21 scale. The developers aimed to create a more comprehensive assessment tool that could capture the complexities of mental health, beyond just depression and anxiety. The DASS-167 was designed to assess three distinct but interrelated constructs: depression, anxiety, and stress. DASS-167

Advantages and Limitations

Advantages:

Interpretation and Cut-Off Scores

Future studies will focus on optimizing the pharmacokinetics and safety of DASS-167, as well as evaluating its efficacy in clinical trials. The development of DASS-167 as a therapeutic agent may provide a much-needed treatment option for patients with COVID-19, particularly those who are resistant or intolerant to existing therapies. What is DASS-167